I’m sure many readers will relate to Kylie’s observation that approval procedures can unintentionally iron out the novel ...

Novo Nordisk has presented new sub‑analyses from the phase 3 OASIS 4 trial at ECO2026, showing that oral semaglutide 25mg ...

The MHRA is establishing a new hub in Northern Ireland to support the region’s fast‑growing life sciences sector, in a move announced on 13 May 2026. Hosted by Invest Northern Ireland, the hub is ...

Asgard Therapeutics has appointed Prof Dr Wolfram Brugger as Chief Medical Officer, strengthening its leadership team as the ...

Enterprise Therapeutics has reported that its phase 2 trial of ETD001, an investigational inhaled epithelial sodium channel blocker, met its primary efficacy outcome in people with cystic fibrosis who ...

Calla Lily Clinical Care has dosed the first patients in its Freedom clinical trial, a nihr‑funded study evaluating the ...

The Scottish medicines consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with ...

PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...

Palisade Bio has released further phase 1a/b analyses of its investigational PDE4 inhibitor prodrug PALI‑2108, adding new ...